Treatment
Olaparib clinical trials
We’re tracking 84 recruiting studies that include Olaparib, each written for real people, not researchers, below.
Recruiting studies
- NCT05463848RecruitingPhase 2
Surgery plus pembrolizumab with olaparib and temozolomide for glioblastoma
This trial tests a combination treatment after surgery for people with glioblastoma that has come back once or twice. It aims to improve control of the tumor by adding immune therapy and targeted DNA-damage treatment along with chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT05900895RecruitingPhase 1
Estradiol plus olaparib for ER-positive breast cancer
This early-stage study tests whether combining estradiol (a form of estrogen) with olaparib (a targeted cancer medicine) can control ER-positive, HER2-negative breast cancer that has spread or come back. It may help by attacking cancer cells in a new way after standard hormone-based treatments.
Lebanon, New HampshireAges 18 years+ - NCT06078787RecruitingPhase 2
Olaparib for advanced pancreatic cancer with PALB2 mutation
This trial tests whether the drug olaparib can help people with advanced pancreatic cancer that has a specific change in the PALB2 gene. You may qualify if your cancer has spread or cannot be removed with surgery and you have already tried at least one other treatment.
ModenaAges 18 years+ - NCT06160843RecruitingPhase 2
Pembrolizumab and olaparib for relapsed peripheral T-cell lymphoma
This trial tests whether combining two targeted drugs, pembrolizumab and olaparib, can help people with peripheral T-cell lymphoma that has come back or not responded to previous treatment. The goal is to find a new option for this type of cancer.
SingaporeAges 21–99 - NCT06217757RecruitingPhase 1/Phase 2
LDRT, immunotherapy, chemo, and olaparib for SLFN-11 positive SCLC
This trial tests a combination of low-dose radiation, an immunotherapy drug (sugemalimab), chemotherapy, and a targeted drug (olaparib) as a first treatment for people with extensive-stage small cell lung cancer that has a specific marker called SLFN-11. The goal is to see if this combination is safe and works better than standard treatment.
Chengdu, SichuanAges 18–75 - NCT07695259RecruitingPhase 4
Olaparib with trastuzumab and pertuzumab for older women with HER2+ breast cancer
This study tests a combination of two antibody drugs (trastuzumab and pertuzumab) plus a targeted pill (olaparib) given before surgery to treat elderly women with HER2-positive breast cancer. The goal is to see if this approach helps shrink tumors or eliminate them entirely before surgery.
Hangzhou, ZhejiangAges 60 years+ - NCT06441747RecruitingPhase 2
Durvalumab and olaparib for advanced bile duct cancer
This trial tests a combination of two drugs—durvalumab (an immunotherapy) and olaparib (a targeted therapy)—for people with advanced bile duct cancer that did not grow after initial treatment with chemotherapy and durvalumab. The goal is to see if this combination can help control the cancer further.
Camperdown, New South WalesAges 18 years+ - NCT06488378RecruitingPhase 1
Axatilimab and olaparib for BRCA/PALB2-mutated breast cancer
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06607692RecruitingPhase 1/Phase 2
LuPARPed: Targeted radiation plus olaparib for certain childhood cancers
This trial tests a combination of a radioactive drug (Lutathera) and a targeted pill (olaparib) for children and teens whose solid tumors have come back or not responded to treatment and show high levels of a specific receptor (SSTR) on scans. The goal is to see if this two-drug approach can shrink tumors or stop them from growing.
Boadilla del Monte, MadridAges 3 years+ - NCT06712472RecruitingPhase 3
Testing maintenance olaparib versus observation after chemoradiation for p53 abnormal endometrial cancer
This trial tests whether taking a daily pill called olaparib after standard chemoradiation can help prevent endometrial cancer with a p53 mutation from coming back. Half of participants will receive olaparib, and the other half will just be watched closely.
AlbiAges 18 years+ - NCT06783127Recruiting
Olaparib for BRCA-related prostate cancer
This trial studies how well olaparib works for men with metastatic castration-resistant prostate cancer that has a BRCA mutation. It looks at results from real-world use, not a controlled study.
NaplesAges Any age - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07371104RecruitingPhase 1
Study of DWZ2501 in advanced BRCA ovarian cancer on olaparib
This trial compares how the body processes a new formulation of olaparib (DWZ2501) versus the standard version. It is for women with advanced, BRCA-mutated high-grade ovarian cancer who are already on or about to start a stable dose of olaparib 300 mg twice daily.
Seoul, Jongno-guAges 19 years+ - NCT07667751RecruitingPhase 2
Study of Ipalotinib with Sunitinib and Olaparib before surgery for advanced ovarian cancer
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
HefeiAges 18–75 - NCT06419179Enrolling by invitationPhase 2
Maintenance therapy for HRD-positive small-cell lung cancer
This trial tests whether a combination of two medications, durvalumab and olaparib, can help keep your extensive-stage small-cell lung cancer from coming back after standard first-line treatment. It is for people whose tumors have a specific genetic feature called HRD.
Cologne, North Rhine-WestphaliaAges 18–120 - NCT04361370Enrolling by invitationPhase 2
Olaparib plus pembrolizumab and bevacizumab after ovarian cancer
This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.
SeoulAges 20 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Tucson, ArizonaAges 18 years+ - NCT06966700RecruitingPhase 3
Study of Sac-TMT in Early High-Risk Breast Cancer
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Gilbert, ArizonaAges 18 years+ - NCT06031805Recruiting
Real-world study of olaparib for prostate cancer
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
AmiensAges 18 years+ - NCT05623319RecruitingPhase 2
Pembrolizumab plus olaparib for extensive small cell lung cancer
This Phase 2 study tests whether combining pembrolizumab and olaparib can improve outcomes in people with extensive-stage small cell lung cancer. It mainly aims to shrink tumors and help control the cancer for longer.
Meldola, Forlì CesenaAges 18 years+ - NCT06739395RecruitingPhase 2
Precision cancer trial for patients out of standard options
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05568212RecruitingPhase 2
Trial of immune combination versus standard care for NSCLC relapse
This Phase 2 trial studies an immune-based drug combination compared with standard care for lung cancer that has come back after chemoradiation and durvalumab. It aims to improve control of the cancer after durvalumab is no longer working.
Roma, RMAges 18 years+ - NCT06525298RecruitingPhase 1/Phase 2
Study of EIS-12656 for solid tumors with DNA repair defects
This trial tests a new drug, EIS-12656, alone or with other treatments, for solid tumors that have specific DNA repair problems called homologous recombination deficiency. It may be an option if your cancer has not responded to prior treatments.
Houston, TexasAges 18 years+ - NCT05536128RecruitingPhase 2
Fulvestrant plus DNA damage drugs after CDK4/6 treatment failure
This Phase 2 trial studies whether combining fulvestrant with medicines that block DNA repair can help treat HR+/HER2- metastatic or inoperable breast cancer that has progressed after endocrine therapy plus a CDK4/6 inhibitor. It also aims to check the safety of this combination and see if it can control the cancer for longer.
SeoulAges 19 years+
Common questions
- Are there clinical trials studying Olaparib?
- Yes. Clin2 currently lists 84 recruiting studies that include Olaparib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Olaparib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Olaparib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Olaparib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.